Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Pharmacol Ther ; 61(5): 554-62, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9164417

RESUMEN

Biotransformation of rifabutin, an antibiotic used for treatment of tuberculosis in patients infected with the human immunodeficiency virus (HIV), and its interactions with some macrolide and antifungal agents were studied in human intestinal and liver microsomes. Both liver and enterocyte microsomes metabolized rifabutin to 25-O-deacetylrifabutin, 27-O-demethylrifabutin, and 20-, 31-, and 32-hydroxyrifabutin. The same products (except 25-O-deacetylrifabutin) were formed by microsomes from lymphoblastoid cells that contained expressed CYP3A4. The apparent Michaelis-Menten constant (Km); approximately 10 to 12 mumol/L) and maximal velocity (Vmax; approximately 100 pmol/min/mg of protein) values for CYP-mediated metabolism were similar in liver and enterocyte microsomes. Deacetylation of rifabutin (Km approximately 16 to 20 mumol/L and Vmax approximately 50 to 100 pmol/min/mg of protein) was catalyzed by microsomal cholinesterase. Clarithromycin, ketoconazole, and fluconazole inhibited CYP-mediated metabolism of rifabutin in enterocyte microsomes equally or more potently than in liver microsomes but had no effect on cholinesterase activity. Azithromycin did not inhibit in vitro metabolism of rifabutin. This study provides evidence that CYP3A4 and cholinesterase are major enzymes that biotransform rifabutin in humans and that intestinal CYP3A4 contributes significantly to rifabutin presystemic first-pass metabolism and drug interactions with macrolide and antifungal agents.


Asunto(s)
Antibacterianos/farmacocinética , Antibióticos Antituberculosos/farmacocinética , Antifúngicos/farmacocinética , Mucosa Intestinal/metabolismo , Microsomas Hepáticos/metabolismo , Rifabutina/farmacocinética , Acetilación , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Antibacterianos/metabolismo , Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/sangre , Antibióticos Antituberculosos/metabolismo , Antifúngicos/administración & dosificación , Antifúngicos/sangre , Antifúngicos/metabolismo , Separación Celular , Colinesterasas/metabolismo , Cromatografía Líquida de Alta Presión , Neoplasias del Colon/cirugía , Citocromo P-450 CYP3A , Sistema Enzimático del Citocromo P-450/metabolismo , Interacciones Farmacológicas , Humanos , Mucosa Intestinal/citología , Macrólidos , Metilación , Oxigenasas de Función Mixta/metabolismo , Rifabutina/metabolismo
2.
J Pharmacol Exp Ther ; 279(3): 1300-9, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8968354

RESUMEN

The in vivo disposition and in vitro metabolism of rifabutin, a new spiropiperidylrifamycin, were studied in rats and in microsomes from rat liver and enterocytes, respectively. After i.v. doses of 1,5, 10 and 25 mg/kg the systemic clearance was 0.7 to 1.0 liters/hr/kg; the volume of distribution was 4.4 liters/kg for the 1 mg/kg dose and 7.4 to 7.7 liters/kg for the 5 to 25 mg/kg doses, and the half-life ranged from 4.4 to 9.1 hr. Urinary and fecal excretion over 0 to 96 hr after i.v. administration of 25 mg/kg [14C]rifabutin accounted for 40.1 and 52.2% of the dose, respectively. Exteriorization of the bile duct showed that approximately 24% of the dose was eliminated in bile, > or = 98% as metabolites. Bioavailability after oral administration of 25 and 1 mg/kg rifabutin was > 90% and 44%, respectively, suggesting significant first-pass metabolism of the lower dose. Concentrations of rifabutin in gastric juice were 10 to 17 times higher than in blood, indicating extensive secretion into the stomach. Experiments with the isolated small intestinal loop demonstrated direct exsorption of the drug into the lumen. The rate of rifabutin metabolism by enterocyte microsomes was > 10 times higher than that by liver microsomes, i.e., 84 and 8 pmol/min/mg protein, respectively. Biotransformation of rifabutin in vivo and in vitro was markedly induced by dexamethasone and inhibited by erythromycin, suggesting that CYP3A is involved in the metabolism of rifabutin. Several metabolites, including 20-OH-rifabutin and 27-O-demethyl-rifabutin, isolated from urine and microsomes were identified by mass spectrometry and nuclear magnetic resonance spectroscopy.


Asunto(s)
Antituberculosos/farmacocinética , Mucosa Intestinal/metabolismo , Microsomas Hepáticos/metabolismo , Microsomas/metabolismo , Rifabutina/farmacocinética , Administración Oral , Animales , Antituberculosos/administración & dosificación , Antituberculosos/sangre , Antituberculosos/orina , Proteínas Sanguíneas/metabolismo , Inhibidores Enzimáticos del Citocromo P-450 , Inhibidores Enzimáticos/farmacocinética , Heces , Jugo Gástrico/metabolismo , Inyecciones Intravenosas , Masculino , Ratas , Ratas Sprague-Dawley , Rifabutina/administración & dosificación , Rifabutina/sangre , Rifabutina/orina , Distribución Tisular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA